9299|10000|Public
5|$|<b>In</b> <b>a</b> <b>clinical</b> {{trial of}} 286 subjects, 53.2% of the 141 given {{immediate-release}} metformin (as opposed to placebo) reported diarrhea, versus 11.7% for placebo, and 25.5% reported nausea/vomiting, versus 8.3% {{for those on}} placebo.|$|E
5|$|Professional {{guidelines}} in the UK recommend {{that patients with}} VA dissection should be enrolled <b>in</b> <b>a</b> <b>clinical</b> trial comparing aspirin and anticoagulation if possible. American guidelines state that the benefit of anticoagulation is not currently established.|$|E
5|$|Similarly, the {{designed}} antioxidant NXY-059 exhibited efficacy {{in animal}} models, {{but failed to}} improve stroke outcomes <b>in</b> <b>a</b> <b>clinical</b> trial. As of November 2014, other antioxidants are being studied as potential neuroprotectants.|$|E
50|$|Lawrence married Birgitta Haraldson <b>in</b> 1971, <b>a</b> <b>clinical</b> {{psychologist}} and expert on autism.|$|R
40|$|Clinical illness[1] with {{laboratory}} {{confirmation of}} infection: • Detection of Chikungunya virus (CHIK-V) nucleic acid (e. g., by RT-PCR) <b>in</b> <b>an</b> appropriate <b>clinical</b> specimen (serum or plasma, or cerebrospinal fluid (CSF) {{in patients with}} neurological symptoms). OR • Viral culture of CHIK-V <b>in</b> <b>an</b> appropriate <b>clinical</b> specimen (serum (preferred) or CSF...|$|R
50|$|May 2011: Solithromycin is <b>in</b> <b>a</b> Phase 2 <b>clinical</b> {{trial for}} serious community-acquired {{bacterial}} pneumonia (CABP) and <b>in</b> <b>a</b> Phase 1 <b>clinical</b> trial with <b>an</b> intravenous formulation.|$|R
5|$|Since {{treatment}} options for relapsed AML are so limited, palliative care or enrollment <b>in</b> <b>a</b> <b>clinical</b> trial may be offered.|$|E
5|$|A {{definitive}} {{diagnosis of}} TB {{is made by}} identifying M. tuberculosis <b>in</b> <b>a</b> <b>clinical</b> sample (e.g., sputum, pus, or a tissue biopsy). However, the difficult culture process for this slow-growing organism can take two to six weeks for blood or sputum culture. Thus, treatment is often begun before cultures are confirmed.|$|E
5|$|Anticonvulsants {{suppress}} epileptic seizures, {{but they}} neither cure nor prevent {{the development of}} seizure susceptibility. The development of epilepsy (epileptogenesis) {{is a process that}} is poorly understood. A few anticonvulsants (valproate, levetiracetam and benzodiazepines) have shown antiepileptogenic properties in animal models of epileptogenesis. However, no anticonvulsant has ever achieved this <b>in</b> <b>a</b> <b>clinical</b> trial in humans. The ketogenic diet has been found to have antiepileptogenic properties in rats.|$|E
5000|$|<b>In</b> <b>a</b> {{preliminary}} <b>clinical</b> trial, <b>a</b> decoction of 25 g fresh {{leaves of}} V. amygdalina was 67% effective <b>in</b> creating <b>an</b> adequate <b>clinical</b> response <b>in</b> African patients with mild falciparum malaria. Of these 32% had complete parasite clearance, but 71% of subjects had recurrence of symptoms.|$|R
25|$|The Alzheimer's drug Gammagard {{fails to}} produce results <b>in</b> <b>a</b> {{large-scale}} <b>clinical</b> trial.|$|R
5000|$|<b>A</b> <b>clinical</b> {{directory}} of services {{can be used}} <b>in</b> conjunction with <b>a</b> <b>Clinical</b> decision support system.|$|R
5|$|The BDI {{suffers from}} the same {{problems}} as other self-report inventories, in that scores can be easily exaggerated or minimized by the person completing them. Like all questionnaires, the way the instrument is administered can {{have an effect on}} the final score. If a patient is asked to fill out the form in front of other people <b>in</b> <b>a</b> <b>clinical</b> environment, for instance, social expectations have been shown to elicit a different response compared to administration via a postal survey.|$|E
25|$|Allopregnanolone {{is being}} studied <b>in</b> <b>a</b> <b>clinical</b> trial by the Mayo Clinic to treat super-resistant status epilepticus.|$|E
25|$|The {{results from}} this {{research}} and the associated hypotheses {{form the basis for}} biological psychiatry and the treatment approaches <b>in</b> <b>a</b> <b>clinical</b> setting.|$|E
50|$|Daclizumab {{has been}} studied <b>in</b> <b>a</b> small <b>clinical</b> trial of people with birdshot chorioretinopathy.|$|R
50|$|<b>In</b> Canada <b>a</b> <b>Clinical</b> Trial Application (CTA) must {{be filed}} before {{starting}} <b>a</b> <b>clinical</b> trial. Health Canada will review theapplication and will notify the sponsor {{within 30 days}} if it {{is found to be}} deficient.|$|R
50|$|Nifurtimox is <b>in</b> <b>a</b> phase-II <b>clinical</b> {{trial for}} the {{treatment}} of pediatric neuroblastoma and medulloblastoma.|$|R
25|$|A {{few days}} later, {{during the course}} of a dental {{procedure}} in Edinburgh, Francis Brodie Imlach became the first person to use chloroform on a patient <b>in</b> <b>a</b> <b>clinical</b> context.|$|E
25|$|Potential {{side effects}} of 5-HTP include heartburn, stomach pain, nausea, vomiting, diarrhea, drowsiness, sexual problems, vivid dreams or nightmares, and muscle problems. Because 5-HTP has not been {{thoroughly}} studied <b>in</b> <b>a</b> <b>clinical</b> setting, possible side effects and interactions with other drugs are not well known.|$|E
25|$|Biomaterials must be {{compatible}} with the body, and there are often issues of biocompatibility which must be resolved before a product can {{be placed on the}} market and used <b>in</b> <b>a</b> <b>clinical</b> setting. Because of this, biomaterials are usually subjected to the same requirements as those undergone by new drug therapies.|$|E
5000|$|... #Caption: Malaria-infected {{mosquitoes}} <b>in</b> <b>a</b> screened cup {{which will}} infect <b>a</b> volunteer <b>in</b> <b>a</b> malaria <b>clinical</b> trial ...|$|R
5000|$|Looking at barcoding {{technology}} <b>in</b> healthcare from <b>a</b> <b>clinical</b> professional standpoint ...|$|R
50|$|In Brazil, tilapia {{fish skin}} {{is being used}} <b>in</b> <b>a</b> new <b>clinical</b> trial to treat burn injuries.|$|R
25|$|Unlike in vivo MRS {{which is}} intensively used in {{clinical}} settings, fMRS is used {{primarily as a}} research tool, both <b>in</b> <b>a</b> <b>clinical</b> context, for example, to study metabolite dynamics in patients suffering from epilepsy, migraine H-MRS findings in migraine patients with and without aura assessed interictally|journal=NeuroImage|date=Feb 15, 2005|volume=24|issue=4|pages=1025–31|pmid=15670679|doi=10.1016/j.neuroimage.2004.11.005}} and dyslexia, and to study healthy brains.|$|E
25|$|Buprenorphine {{has been}} used in the {{treatment}} of the neonatal abstinence syndrome, a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal. Use currently is limited to infants enrolled <b>in</b> <b>a</b> <b>clinical</b> trial conducted under an FDA approved investigational new drug (IND) application. An ethanolic formulation used in neonates is stable at room temperature for at least 30 days.|$|E
25|$|In {{order to}} {{accomplish}} this, {{we must have}} facilities that will enable our faculty to do proficient work in every line. This will require an investment <b>in</b> <b>a</b> <b>clinical</b> hospital and in dispensary work. But all this is absolutely necessary to give our {{young men and women}} who take the medical course a proficient training in rational methods of treatment.|$|E
5000|$|Computer-based CBT-I {{was shown}} to be {{comparable}} in effectiveness to therapist-delivered CBT-I <b>in</b> <b>a</b> placebo-controlled <b>clinical</b> study.|$|R
50|$|According to The Beljanski Foundation, <b>In</b> 1994, <b>A</b> <b>clinical</b> {{trial with}} the PB-100 was {{organized}} at the University Hospital Lapeyronie {{and published in}} Deutsche Zeitschrift für Onkologie.|$|R
50|$|<b>In</b> Kenya, <b>a</b> <b>clinical</b> officer {{graduates}} with <b>a</b> dual diploma <b>in</b> <b>clinical</b> {{medicine and}} surgery from an accredited institution and receives a registration certificate {{from the government}} and a license to practice medicine after completing a four-year training program which follows the North American four-year MD or DO medical school model instead of the six-year MBChB model that is more common <b>in</b> commonwealth countries. <b>A</b> <b>clinical</b> officer is therefore able to graduate and join the workforce <b>in</b> <b>a</b> minimum of four calendar years.|$|R
25|$|In some {{countries}} like UK exists the clinical attachment {{system that is}} defined as a period of time when a doctor is attached to a named supervisor <b>in</b> <b>a</b> <b>clinical</b> unit, with the broad aims of observing clinical practice in the UK and the role of doctors and other healthcare professionals in the National Health Service (NHS).|$|E
25|$|Primidone is not {{the only}} {{anticonvulsant}} used for essential tremor; the others include topiramate (Topamax) and gabapentin (Neurontin). Other pharmacological agents include alprazolam (Xanax), clonazepam (Klonopin), atenolol, sotalol, nadolol, clozapine, nimodipine, and botilinum toxin A. Many of these drugs were less effective (according to Table 1), but a few were not. Only propranolol has been compared to primidone <b>in</b> <b>a</b> <b>clinical</b> trial.|$|E
25|$|Unlike in vivo MRS {{which is}} intensively used in {{clinical}} settings, fMRS is used {{primarily as a}} research tool, both <b>in</b> <b>a</b> <b>clinical</b> context, for example, to study metabolite dynamics in patients suffering from epilepsy, migraine and dyslexia, and to study healthy brains. fMRS {{can be used to}} study metabolism dynamics also {{in other parts of the}} body, for example, in muscles and heart; however, brain studies have been far more popular.|$|E
50|$|<b>In</b> <b>a</b> human <b>clinical</b> trial {{published}} in 2003, theaflavins {{were found to}} reduce blood cholesterol levels, both total and LDL.|$|R
5000|$|Is a {{registered}} healthcare practitioner {{with a minimum}} of 5 years clinical experience (2 years <b>in</b> <b>a</b> senior <b>clinical</b> role) ...|$|R
40|$|Clinical illness[1] with {{laboratory}} {{confirmation of}} infection: • Seroconversion or significant (i. e., fourfold or greater) rise in antibody titre to Rickettsia prowazekii by IFA in acute and convalescent phase specimens ideally taken ≥ three weeks apart[2] OR • Detection of R. prowazekii nucleic acid (e. g., PCR) <b>in</b> <b>an</b> appropriate <b>clinical</b> specimen (e. g., blood) OR • Detection of R. prowazekii <b>in</b> <b>an</b> appropriate <b>clinical</b> specimen by immunostaining (e. g., blood...|$|R
